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Cannabinoids Suppress Dendritic Cell-Induced T Helper Cell Polarization 
Tangying (Lily) Lu 
 
 ABSTRACT  
 
     Cannabinoids suppress Th1 immunity in a variety of models including 
infection with the intracellular pathogen Legionella pneumophila (Lp).  To 
examine the cellular mechanism of this effect, mouse bone marrow-derived 
dendritic cells (DCs) were studied following infection and drug treatment.  DCs 
produced high levels of IL-12p40 following Lp infection.  THC suppressed this 
cytokine response in a concentration-dependent manner and the 
endocannabinoids 2-arachidonoyolglycerol and virodhamine less potently 
suppressed cytokine production.  DCs expressed mRNA for cannabinoid 
receptor 1 (CB1), CB2, and transient receptor potential vanilloid type 1 (TRPV1); 
furthermore, inhibition of Gi signaling by adding pertussis toxin completely 
attenuated the suppression induced by low concentrations of THC but not at high 
concentrations.  In addition, the THC suppression was partially attenuated in DC 
cultures from CB1 and CB2 knockout mice and in cultures from normal mice co-
treated with THC and cannabinoid receptor antagonists.  Cytokine suppression 
was not attenuated by pretreatment with the TRPV1 antagonist capsazepine, 
 ix
suggesting that Gi signaling and cannabinoid receptors, but not TRPV1, are 
involved in THC-induced suppression of DC potential to polarize the 
development of naïve T cells to be Th1 cells.  Besides IL-12, THC suppressed 
other DC polarizing characteristics such as the expression of MHC class II and 
co-stimulatory molecules CD86 and CD40, as well as the Notch ligand Delta 4.  
However, THC treatment did not affect other DC functions such as intracellular 
killing of Lp and Lp-induced apoptosis.  Testing the capacity of THC to suppress 
DC polarizing function with T cells showed that DCs infected in vitro with Lp were 
able to immunize mice when injected prior to a lethal Lp infection; however, the 
immunization potential along with Th1 cytokine production was attenuated by 
THC treatment of the cells at the time of in vitro infection.   In addition, THC-
treated and Lp-infected DCs poorly stimulated primed splenic CD4 T cells in 
culture to produce IFN-gamma (IFN-γ); however, this stimulating deficiency was 
reversed by adding recombinant IL-12p40 protein to the cultures.    In conclusion, 
the data suggest that THC inhibits Th1 polarization by targeting essential DC 
functions such as IL-12p40 secretion and the maturation and expression of co-
stimulatory and polarizing molecules.   
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INTRODUCTION 
 
Cannabis products and cannabinoids 
 
Cannabis is one of the oldest psychotropic drugs known in human history 
and has been used from the earliest records. In 2737 BC, Shen Nung, an 
emperor of ancient China, had described the properties and therapeutic uses of 
cannabis in his compendium of Chinese medicinal compounds (98).  Two main 
preparations derived from cannabis are marijuana and hashish.  Marijuana is a 
green, brown, or gray mixture of dried leaves, stems, seeds, and flowers of the 
hemp plant (cannabis sativa) while hashish is the viscous resin of the Indian 
hemp plant (97).  Despite the fact that cannabis and its products have been 
widely noted for their effects as an analgesic, appetite stimulant, antiemetic, 
muscle relaxant and anticonvulsant for centuries (178), it was not until the 1940s 
that scientists were able to purify and define the structures of the cannabis plant, 
including more than 60 dibenzpyrene components known as cannabinoids.  The 
major psychoactive ingredient of cannabis is delta-9-tetrahydrocannabinol, 
usually termed as THC.  Other cannabinoids in cannabis such as delta-8-
tetrahydrocannabinol (Δ8THC), cannabinol (CBN), cannabidiol (CBD), 
cannabicyclol (CBL), cannabichromene (CBC) and cannabigerol (CBG) are 
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present in small quantities and have little psychoactive effects compared to THC 
(14); however, it has been suggested they may have synergistic effects in 
combination with THC (8). 
 
Cannabinoid receptors 
                      
Cannabinoids usually exert their actions by binding to specific receptors 
and two types of cannabinoid receptor have been decribed to date.  These 
receptors are found in mammals, birds, fish, and reptiles (49).  Cannabinoid 
receptor type 1 (CB1), originally cloned by Matsuda et al. in 1990 from a rat brain 
cDNA library by a probe derived from the sequence of bovine substance-K 
receptor, exhibits 97 to 99% amino acid sequence identity across species (30, 
57, 114, 115).  CB1 has been demonstrated in high levels in the central nervous 
system (CNS) and is predominantly found presynaptically expressed, and 
associated with the behavioral effects following cannabinoid usage, such as loss 
of short-term memory, dizziness, ataxia and sedation (34).  Peripheral 
expression of CB1 has also been found in many peripheral tissues including 
heart, vascular endothelium, small intestine, liver (144, 176) and in the cells of 
immune system such as splenocytes (78, 136), mast cells (163) and DCs (43, 
113).  Cannabinoid receptor type 2 (CB2) cloned in 1993 by Munro and 
associates from a human HL60 promyelocytic cell line library, exhibits 48% 
homology with CB1 (129).  CB2 expression differs from CB1 in that it is relatively 
undetectable in the CNS (129, 164) except for microglia that express both CB2 
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and CB1 (54, 183) (26).  CB2 is expressed in a high level in the tissues of 
lymphoid system including the thymus, tonsils, bone marrow and spleen (56, 87, 
105).  Both receptors are coupled to Gi proteins to negatively regulate adenylyl 
cyclase and cAMP accumulation.  This Gi protein-induced signal can be blocked 
by pertussis toxin (71). 
 
Endocannabinoids and synthesized cannabinoids 
 
Discovery of the cannabinoid receptors in humans and animals led first to 
the prediction and later to the actual findings of endogenous ligands termed 
endocannabinoids.  Anandamide (Arachidonoylethanolamide; AEA) (40) and 2-
arachidonylglycerol (2-AG) (119), both derivatives of arachidonic acid, are the 
most studied endocannabinoids.  These endocannabinoids participate in the 
regulation of neurotransmission (10, 41, 69) and many biological effects 
associated with marijuana connabinoids.  2-AG is a full and potent agonist for 
both CB1 and CB2, while AEA is more selective to CB1 than to CB2 (70).  AEA 
has also been shown to bind vanilloid receptors that are heat-gated, cation 
channels, sensitive to the vanilloid compound capsaicin and its analogues (196).  
Many studies have shown that upon stimulation with agents such bacteria-
derived lipopolysaccharide (LPS), immune cells, including macrophages (42), 
DCs (113) and peripheral-blood mononuclear cells  (PBMCs) (107) release the 
endocannabinoids 2-AG and AEA that may act as chemotactants for leukocytes 
and take part in immune regulation (83).  A novel endocannabinoid, Virodhamine, 
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also a derivative of arachidonic acid, has been described recently as an agonist 
acting on both CB1 and CB2.  Virodhamine was shown to be highly produced in 
spleen tissues suggesting its potential role in immunomodulation (148).  Other 
endogenous cannabinoids including N-arachidonyldopamine (NADA) and 
Docosatetraenylethanolamide (DEA) have also been described.  NADA is 
produced in mammalian nervous tissue and acts at vanilloid and cannabinoid 
receptors with more selectivity toward CB1 than CB2 (16, 36, 73).  DEA is an 
endogenous ligand selectively activating CB1, and produced by astrocytes.  It 
acts as a cannabimimetic in vivo, causing hypothermia, analgesia, motor activity 
inhibition and catalepsy (12, 61). 
In addition to these naturally occurring cannabinoids and 
endocannabinoids, also many structural analogues of cannabinoids have been 
synthesized in a number of laboratories.  Some of these analogues include 
arachidonyl-2-chloroethylamide (ACAE), ajulemic acid (AJA), methyl arachidonyl 
fluorophosphonate (MAFP), JWH-133 and CP55, 940.  Among these analogues, 
ACEA has high selectivity for CB1 (64, 70).  AJA is a nonpsychoactive, synthetic 
analog of a metabolite of THC with relatively low affinity for cannabinoid 
receptors but some demonstrated efficacy in animal models of chronic pain (46) 
and inflammatory diseases (24).  MAFP is a potent, irreversible inhibitor of AEA 
amidase, the enzyme responsible for AEA hydrolysis, and a selective ligand for 
CB1 (39, 110).  JWH-133 is a highly selective agonist for CB2 while  CP55, 940 
has high affinity for both CB1 and CB2 (71).  Some of these analogues of 
cannabinoids possess low CB1 binding resulting in low psychoactivity.  Therefore, 
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these analogues may have potential therapeutic usage in immune inflammatory 
diseases associated with dysregulation of cannabinoid receptor signaling. 
 
Receptors involved in cannabinoid effects 
 
Since both CB1 and CB2 are Gi protein-coupled receptors, the signaling 
mechanisms involved in cannabinoid effects are associated with activation of Gi 
proteins.  It is well known that these heterotrimeric proteins are activated by 
ligand binding to a seven-transmembrane G protein-coupled receptor (GPCR) 
causing a conformational change, promoting an exchange of GDP for GTP by 
the Gα subunit, and the dissociation of Gα from the Gβγ dimmer.  Activated Gα and 
Gβγ subunits subsequently modulate specific downstream signaling pathways, 
and therefore relay information intracellularly in response to various extracellular 
receptor stimulants (117).  Dysregulated G-protein signaling leads to pathologies 
in numerous organ systems and many important classes of medications can 
modify GPCR signaling pathways either directly or indirectly (155).  A number of 
studies suggested that Gi signaling was involved in cannabinoid effects mainly 
through binding to either CB1 or CB2 (69).  However, although currently there are 
only two known cannabinoid receptors, other known or yet to be identified 
receptors or non-receptor mediated mechanisms may be involved in cannabinoid 
effects.  For example, the synthetic cannabinoid AJA, which has potent anti-
inflammatory effects but low affinity to CB2, is known to bind directly to and 
activate the peroxisome proliferator-activated receptor gamma (PPAR-gamma), a 
 6
pharmacologically important member of the nuclear receptor superfamily (24, 
101).  Similarly, the plant-derived cannabinoid CBD has immunosuppressive 
effects and binds weakly to both CB1 and CB2.  One recent study demonstrated 
that the CBD effect could be reversed by an A2a adenosine receptor antagonist 
and abolished in A2a receptor knockout mice providing a non-cannabinoid 
receptor mechanism mediated by cannabinoids (27).  Also, it has been shown 
that the endocannabinoid AEA can activate TRPV1 receptors (102, 108).  
However, some cannabinoid effects seemed to be mediated by non- CB1, non- 
CB2 and non-TRPV1 receptor mechanisms that remain to be elucidated (65, 124, 
143).  Overall, the signaling pathway involved in cannabinoids is more diverse 
than originally speculated and some effects are not mediated by the already 
known cannabinoid receptors. 
 
Effects of cannabinoids on innate immunity 
 
Innate immunity is critical in immune surveillance against pathological 
infection agents (188).  Macrophages and neutrophils are mediators of innate 
immunity and can recognize, phagocytize and kill microbes through the activation 
of several enzymes including oxidases and inducible nitric oxide synthase 
(iNOS); these enzymes produce the toxic reactive oxygen intermediates (ROI) 
and nitric oxide (NO) that not only kill microbes but cause inflammation and 
tissue damage (162).  It has been shown that THC, through inhibition of cAMP 
signaling, inhibits iNOS and NO production by macrophages stimulated with LPS 
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(77).   In similar studies, lung alveolar macrophages collected from marijuana 
smokers exhibited limited antimicrobial activity.  However, treatment with 
granulocyte/macrophage colony-stimulating factor (GM-CSF) or IFN-γ restored 
these cells to produce NO and antibacterial efficiency (159, 165).  In addition, the 
endogenous cannabinoid AEA has been shown to suppress, though not as 
strong as THC, the expression of cytokines such as IL-1, IL-6 and TNFα by rat 
microglial cells, the macrophage cell type in brain (149).  Gongora et al. recently 
showed that synthetic cannabinoid CP55, 940 blocked the expression of MHC 
class II molecules induced by IFN-γ on the surface of microglial cells (58).  Also 
CP55, 940, but not AEA treatment, inhibited superoxide production in neutrophils 
(94), while macrophage proteolytic and lysosome processing could be 
suppressed by THC (116).  It was recently reported that JWH-133 inhibited the 
production of IL-12p40 and enhanced IL-10 by LPS- or Theiler's virus -activated 
macrophages (32).  In addition, it has been demonstrated that the main 
nonpsychoactive component of marijuana cannabidiol (CBD) significantly 
modulated murine macrophage cytokine production and chemotaxis (160).   
Natural killer (NK) cells, which are a class of innate immune cells, can 
rapidly respond to intracellular infections with viruses or bacteria by direct killing 
of the infected cells (60).  It has been shown that THC can suppress NK cell 
function in both animal models (85, 142) and humans (169).  A recent study 
using marijuana users demonstrated that cannabis induced a significant 
decrease in the absolute number of NK cells as well as T and B cells in 
peripheral blood (48).  In other studies, CB1 and CB2 antagonists were shown to 
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partially reverse the THC- inhibited NK cytolytic activity in mice (111).  In 
addition, the endogenous cannabinoid 2-AG, but not AEA, has been shown to 
induce the migration of KHYG-1 cells, an NK leukemia cell line, and human 
peripheral blood NK cells (82).  These studies demonstrated that various 
cannabinoids are capable to significantly modulate (mostly suppress) the innate 
immune cell functions which include migration, phagocytosis and processing 
foreign pathogens, cytokine production, and killing of target cells.  Innate 
immunity can also highly impact the development of adaptive immunity.  
Therefore cannabinoid modulation of innate immune cells might also modulate 
the activation and development of T cells and B cells. 
 
Effects of cannabinoids on adaptive immunity 
 
T helper cells (Th) are CD4+ T cells that through a variety of mechanisms 
provide help for activating adaptive immunity.  Th cells generate their effects by 
releasing cytokines and/or by direct cell-cell interactions.  T helper cytokines and 
co-stimulatory molecules interact with macrophages, B cells and CD8+ killer cells 
to produce the effector mechanisms of adaptive immunity such as activated 
macrophages, antibodies and killer T cells to clear the invading pathogens (137).  
Based on the types of cytokines Th cells produce, they are classified into two 
subtypes, i.e., T helper cell type 1 (Th1) and type 2 (Th2).  Th1 cells produce IL-
2, IFN-γ and TNF-β, which promote the development of cell-mediated immunity, 
while Th2 cells produce IL-4, IL-5, IL-10 and IL-13, and can activate humoral 
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immunity, mainly directed against extracellular infections (4, 45).  Recent studies 
show that many immune disorders are attributable to the collapse of the system 
controlling the proportion of Th1 and Th2 cells. For example, allergy, multiple 
sclerosis, and organ-specific autoimmune disease have pathology associated 
with aberrant Th1 and Th2 polarization (92, 100, 128).  Moreover, restoration of 
the proper balance between Th1 and Th2 cells is generally considered essential 
in the treatment of tumors, which are generated when cellular immunity is 
affected by immunosuppressive factors (93).  
Marijuana smoking increases susceptibility to infections (84) and is a risk 
factor in cancers of the respiratory system (174).  Many studies indicate that 
cannabinoids have a Th biasing effect that shifts Th1 to Th2 response.  Our 
group previously examined the effect of THC on host immune resistance to 
infection with Legionella pneumophila (Lp) (89, 134).  Lp is a facultative, Gram-
negative, intracellular bacterial pathogen that causes Legionnaires’ disease in 
healthy as well as especially immunocompromised individuals (55).  Host 
resistance to this pathogen depends on activation of Th1 cells, cell-mediated 
immunity, and acute phase cytokine mobilization (17, 133, 175), and THC was 
shown to suppress Th1 immunity and concomitantly to enhance Th2 
development that could not mediate the protection against Lp infection (89, 134).  
These studies suggested that cannabinoids may have the unique character of 
biasing immune responses away from Th1 and toward Th2.  The mechanism of 
the T helper biasing effect is unclear, but in mice involves activation of 
cannabinoid receptors, suppression of serum interleukin-12 (IL-12) and splenic 
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IL-12 receptor expression, suppression of serum interferon γ (IFN-γ) (89), and an 
increase in the Th2 biasing transcription factor GATA3 (86). 
Also the effect of THC on Th basing has been observed in other animal 
models.  Zhu et al. demonstrated THC decreased the production of Th1 cytokine 
IFN-γ and increased the immunosuppressive cytokines IL-10 and TGF-β, 
disrupted host anti-tumor immunity and promoted lung tumor growth (192). 
Similarly, a recent paper by Mckallip et al. demonstrated THC enhanced breast 
cancer growth and metastasis along with increased Th2 but decreased Th1 
related gene expression (118).  It was not clear in this study if the suppression of 
cytokines was due to the enhanced Th2 response or the activation of T 
regulatory cells, which are characterized as CD4+CD25+Foxp3+ and able to 
produce IL-10 and TGF-β (146).  The alteration effect of THC on the balance of 
Th1 and Th2 cytokines was also observed in human T cell cultures stimulated 
with allogeneic DCs (191) and in peripheral blood mononuclear cells (PBMCs) 
isolated from marijuana smokers (140).  Therefore, it has been implicated that 
cannabinoids have T helper biasing effect.  However, the precise molecular and 
cellular mechanisms for these effects are far from defined; also the involvement 
of cannabinoid receptors (CBRs) remains unclear.  
 
Effects of cannabinoids on DCs 
 
DCs are professional antigen-presenting cells (APCs) that are generated 
in the bone marrow and migrate as precursor cells to sites of potential entry of 
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pathogens.  During the past decade, intensive studies have demonstrated that 
DCs are central to the integration of innate and adaptive immunity (11). In 
contrast to B and T lymphocytes, DCs express many pattern recognition 
receptors including various Toll-like receptors (TLRs) and are therefore uniquely 
able to sense stimuli such as bacterial and viral infection as well as tissue 
damage and necrosis (47).  Immature DCs residing in tissues respond to 
antigenic signals in the environment, leading to their maturation and migration to 
lymphoid organs.  During this process, the phenotypic characteristics and 
functions of these cells change, including reduced phagocytic capacity and 
increased secretion of high levels of immunostimulatory cytokines such as IL-12 
and expression of MHC and co-stimulatory molecules (79). Also, expression of 
the polarizing Notch ligands, Jagged and/or Delta, is increased (6).  Matured DCs 
then acquire the ability to direct the development of adaptive immunity including 
shaping the type of Th cell response (79).  In addition, it is becoming evident that 
DCs also play a critical role in amplifying the innate immune response, either 
directly by stimulating NK cells and other innate immune cells (37) or indirectly 
through orchestrating Th development.  Studies have delineated the role of DCs 
in immune responses to a variety of pathogens, including bacteria, viruses, and 
protozoan parasites as well as to tumors (13, 126).   
Little is known, however, concerning the role of cannabinoids on DCs.  
Only recently it has been shown that both CB1 and CB2 receptors are expressed 
on human and murine DCs (43, 113); and several endocannabinoids including 
AEA and 2-AG were found to be present in lipid extracts from immature DCs 
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(113).  These findings suggest the possible involvement of DCs in cannabinoid 
modulatory effects on immunity including THC induced shift from Th1 to Th2 
effect.  The current project, therefore, studys the immunomodulatory effect of 
cannabinoids on mouse bone marrow-derived DCs during Lp infection. 
 
Project significance 
 
The current study examines a model of infection using Lp infected DCs 
which were treated with THC and related pharmacological agents.  This study 
uncovers detailed mechanisms of the immunomodulatory effects of cannabinoids 
on DCs especially during the primary stages of infection and biasing toward T 
helper immunity.  Moreover, even though a Th shift might be detrimental in the 
case of Lp and other intracellular pathogenic infections in mice and human 
because Th1 immunity is critical to recovery from these infections, in certain 
autoimmune diseases, for example systemic lupus erythematosus (SLE), the 
enhanced expression of Th1 immunity to self proteins can be a major cause of 
the development of disease (125).  In this instance, cannabinoids might have 
therapeutic potential by suppressing Th1 immunity.  The traditional focus for 
immunosuppressive drugs has been on lymphocytes as the primary cellular 
target.  However, it is now understood that several classical and newly 
established immunosuppressive drugs interfere with immune responses in the 
early stages by suppressing DC differentiation, maturation and activation (59).  
Moreover, DCs have been suggested as immunotherapy for a number of cancers 
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(21, 132) and as adjuvants to induce Th1 and Th2 immunity (81).  This study 
provides a close examination of cannabinoids on DC biology and clues to the use 
of these drugs in the pharmacological manipulation of immune responses.  
Overall, the results gathered will better define the public health risk of smoking 
marijuana and exposure to other cannabinoid agents as well as provide potential 
uses for these agents as immunomodulating and anti-inflammatory therapeutics.    
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OBJECTIVES 
 
The studies to be conducted will investigate the impact of cannabinoids on 
mouse bone marrow-derived DCs.  Previous studies suggested that 
cannabinoids bias Th polarization and we believe that cannabinoids influence the 
functions of DCs which are key to the polarizing event.  Preliminary results from 
our laboratory showed that THC treatment of murine bone marrow-derived DCs, 
infected with Lp, suppressed the production of IL-12p40 (Figure 1), a key protein 
involved in Th1 polarization.  These findings led to the hypothesis that 
cannabinoids, such as THC, suppress immunity against Lp infection by inhibiting 
the Th1 polarization function of DCs.   In order to verify this hypothesis, the 
following aims are proposed. 
 
Aim 1. To determine the effect of cannabinoids on the polarizing phenotype 
of DCs infected with Lp 
 
Evidence is accumulating that endocannabinoids are physiologically 
essential molecules in various biological systems including the immune system 
(83, 87).  However, the specific immunomodulatory effects of cannabinoids on 
DCs have not been fully investigated (84).  DCs are the major source of IL-12 
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production in the early stages of an infection, and IL-12 is the key cytokine to 
direct Th naive cell development to Th1 cells (137).  We will study the kinetics of 
IL-12p40 production in Lp-infected  DC cultures and will determine the effect of 
THC treatment on the quantitative and qualitative aspects of IL-12p40 
production.  Similar experiments will be done using LPS as stimulant. In addition, 
we will examine the effect of other cannabinoid receptor agonists on IL-12p40 
including the endocannabinoids 2-AG and Virodhamine, as well as CB1-selective 
agonists ACEA, AJA, Methanandamide, MAFP, DEA and NADA, and the CB2-
selective agonist, JWH-133.  A variety of DC characteristics in addition to IL-
12p40 production are known to influence T cell subset development (79).  
Therefore, we will also examine the effect of THC on the expression of DC 
maturation markers including MHC class II and the co-stimulatory molecules 
CD86 and CD40, and the Notch ligand Delta 4 (6).  In addition, DC functions 
such as Lp intracellular killing ability and Lp induced-apoptosis will also be 
studied.  
 
 
Aim 2. To determine the role of cannabinoid receptors in drug effects on 
DC polarization 
 
Both CB1 and CB2 have been reported to be involved in the THC-induced 
attenuation of IL-12 production in THC-treated mice infected with Lp (89).  We 
detected the mRNA expression of both cannabinoid receptors in DCs by using 
 16
semi-quantitative RT-PCR.  CB1 and CB2 are Gi protein-coupled receptors.  Gi 
signaling is sensitive to pertussis toxin inhibition and has been suggested to be 
able to suppress IL-12 production (19, 89).  We therefore will examine if the role 
of Gi-mediated signaling pathways in the suppression of IL-12p40 by THC in 
experiments using the Gi inhibitor, pertussis toxin.  Also, experiments will be 
performed using CB1-/- mice (194) and CB2-/- (23) mice in combination with 
receptor antagonists to fully examine the involvement of cannabinoid receptors.  
Moreover, other receptors, such as TRPV1, have also been reported to mediate 
cannabinoid effects (180). We, therefore, will examine its role in THC effects on 
IL-12p40 production by pretreatment with the TRPV1 antagonist capsazepine.  In 
addition, the intracellular activation of MAP kinases has been shown to regulate 
IL-12 production (18, 179, 186); by using specific antagonists MAP kinase 
involvement in Lp induced IL-12p40 and suppression byTHC will be studied.       
 
Aim 3. To determine the effect of THC treatment on the T helper polarizing 
function of DCs 
 
Effective protection from infections with intracellular microorganisms 
needs the induction of cell-mediated immune responses requiring the activation 
of Th1 cells stimulated by the interaction between naïve T cells and polarized 
DCs (123).  To examine the mechanism of the effect of THC on the polarizing 
function of DCs with antigen (Ag)-specific T cells, Lp-infected DCs will be treated 
with THC and then co-cultured with Lp-primed splenic CD4+ T cells to detect the 
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protein levels of IFN-γ and IL-12p40 in supernatants.  Furthermore, we will 
examine the immunization effect of Lp-infected DCs treated in culture with either 
DMSO or THC to induce protective immunity in mice when injected prior to Lp.  
In these experiments, mice mortality will be monitored and Th1 and Th2 
cytokines measured in cultures of splenocytes from mice administrated DCs 
treated under different conditions.   
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MATERIALS AND METHODS 
 
Mice 
 
BALB/c and C57BL/6 mice, 7 week of age, were obtained from NCI 
(Fredericksburg, MD).  Cannabinoid CB1 receptor and CB2 receptor gene 
deficient mice (CB1-/- and CB2-/-) on C57BL/6 background were bred by USF 
animal facility staff from stocks provided by Dr. Andreas Zimmer (CB1-/-, 
University of Bonn) and Dr. Nancy Buckley (CB2-/-, California State Polytechnic 
U.).  The mice were housed and cared for in University of South Florida Health 
Sciences animal facility, which is fully accredited by the American Association for 
Accreditation of Laboratory Animal Care. 
 
Reagents 
 
THC, cannabinoid CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-
chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide 
hydrochloride (SR141716A), and cannabinoid CB2 receptor antagonist N-[(1S)-
endo-1,3,3-trimethyl bicycle [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-
methylbenzyl)-pyrazole-3-carboxamide (SR144528) were obtained from the 
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Research Technology Branch of the National Institute on Drug Abuse (Rockville, 
MD).  SR141716A, SR144528 and THC were first diluted in dimethyl sulfoxide 
(DMSO) at 20 mg/ml and then in 5% fetal calf serum RPMI 1640 medium to a 
concentration of 0.01-10 µM.  2-Arachidonoylglycerol (2-AG), Virodhamine, 
Methanadamide, ACEA, MAFP, DEA, NADA and CP55,940 were purchased 
from Tocris (Bristol, UK).  AJA was obtained from Dr. Sumner Burstein 
(University of Massachusetts, MA) and JWH-133 from Dr. John Huffman 
(Clemson University, Clemson, South Carolina).  Pertussis toxin (Gi signaling 
inhibitor) was purchased from Sigma (St. Louis, MO).  Capsazepine (TRPV1 
antagonist) was purchased from ALEXIS (San Diego, CA).  Pertussis toxin was 
dissolved in medium to a concentration of 0.01-1.0 ng/ml.  Other cannabinoids 
and capsazepine were dissolved in medium to a concentration of 0.01-10 µM.  
MAP kinases antagonists UO126, SP600125 and SB203580 were purchased 
from Tocris (Bristol, UK). 
 
Bacteria 
 
A virulent strain of Lp (M124), serogroup 1, was obtained from a case of 
Legionellosis from Tampa General Hospital (Tampa, FL) and cultured on BCYE 
medium (Difco, Detroit, MI) as described previously (89).  Bacteria from colonies 
of 48 hr cultures were suspended in pyrogen free saline and adjusted 
spectrophotometrically to a working concentration.   
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Preparation and treatment of bone marrow derived DCs 
 
Bone marrow cells were collected from femurs and tibias of the BALB/c 
and C57BL/6 wildtype as well as CB1-/- and CB2-/- mice at 8 to 12 weeks age.  
Cells were suspended at 1.0 x 106/ml and cultured overnight in 6-well cell culture 
plates (GIBCO-Costar, Cambridge, MA) in RPMI1640 medium supplemented 
with 5 µM 2-mercaptoethamol, 2 mM L-glutamine, 1% antibiotic/antimycotic 
solution (Sigma), 5% heat-inactivated fetal calf serum (HyClone, Logan, UT) and 
10ng/ml granulocyte/macrophage colony-stimulating factor (GM-CSF) (BD-
Pharmingen, San Diego, CA).  Non-adherent cells were removed and the 
adherent cells were incubated with fresh GM-CSF-containing medium for an 
additional 7-9 days, during which time the bone marrow-derived DCs became 
nonadherent and were harvested.  The purity of the obtained DCs was 
determined by flow cytometry staining using fluorochrome-conjugated 
monoclonal antibodies to CD11b and CD11c (BD-Pharmingen).  The purity was 
about 100% CD11b+ and greater than 75% CD11c+ cells.  These DCs were 
either uninfected or infected with Lp at ratio 10:1 for 30 to 35 min.  DCs were 
then washed two times to remove non-internalized Lp and re-suspended to106 
cells/ml.  The cells were treated with different cannabinoids at various 
concentrations or with the highest concentration of DMSO or ethanol (vehicle 
control). To study the mechanisms involved in THC effect, the DCs were 
pretreated with SR141716A or SR144528 at 0.01, 0.05, 0.1 and 0.5 μM or with 
capsazepine at 0.01, 0.1, and 1.0 μM.  In the study with pertussis toxin, cells 
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were cultured for 18 hr with 0.01-1.0 ng/ml pertussis toxin before infected with 
Lp.  When LPS (Sigma) was used as stimulator, DCs were incubated with LPS 
0.01-1 µg/ml and supernatants were collected for cytokine detection at different 
time points as indicated.  In studies with CD4 T cells, cells were obtained from 
mice intravenously (iv) infected (primed) with a sub-lethal dosed of Lp (7 x 106) 
and the spleens were removed 5 days post-infection.  The T cells were isolated 
from the splenocytes by mouse T cell Enrichment Columns (R&D system, 
Minneapolis, MN) and CD4+ T cells were negatively selected from the purified T 
cells with CD4 enrichment magnetic bead kits (BD-Pharmingen).  Isolated CD4 T 
cells were then dispensed in 24-well cell culture plates (GIBCO-Costar) and co-
cultured with DCs (CD4: DC = 10:1) in either the absence or presence of 
recombinant IL-12p40 (BD-Pharmingen) for 24 hr followed by cytokine analysis.    
 
Cell surface marker analysis by flow cytometry 
 
To evaluate the effects of THC on MHC class II, CD86 and CD40 
expression on DCs, cells, either uninfected or infected with Lp, were treated with 
DMSO or THC 10 µM for 48 hr.  Following incubation, the cells were treated with 
fluorochrome-conjugated mAbs (BD-Pharmingen) at 4°C for 30 min, and then 
washed in PBS containing 2% BGS, and fixed in 1% paraformaldehyde.  Cells 
were analyzed using FACScan (Becton Dickinson, Mountain View, CA).  The 
instrument is equipped with lasers tuned to 488 nm and to 635 nm.  The following 
fluorochrome-conjugated mouse mAbs were used for DC surface marker 
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staining: PE-conjugated anti-MHC class II; PE-conjugated anti-CD86; and PE-
conjugated anti-CD40 (BD Pharmingen).  
 
Bacteria growth determined by CFU assay 
 
After 24 hr infection, spleens from infected mice were homogenized in 
Hanks balanced salt solution (HBSS).  In studies of Lp growth in DC cultures, 
cells were lysed by with 0.1% saponin (Sigma) and diluted in HBSS.  
Homogenized spleens or lysed DCs were plated on BCYE agar plates and 
incubated at 37°C for 72 hr.  CFU counts were determined on an AutoCount 
apparatus (Dynatech Labs, Chantilly, Va.).   
 
Cell viability and apoptosis detection 
 
DC viability and apoptosis were detected using the Annexin V-FITC kit ( 
BD-Pharmingen).  Briefly, uninfected or infected cells (105), treated with DMSO 
(LpDC/DMSO) or THC 10 µM for 24 hr (LpDC/THC), were washed twice with 
PBS, and incubated with Annexin V-FITC (5 µl) and propidium iodide (5 µl) in 
binding buffer for 15 min. Early apoptotic cells (Annexin V positive and propidium 
negative) and late apoptotic or dead cells (Annexin V positive and propidium 
positive) were quantitated by flow cytometry.   
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Cytokine detection by ELISA 
 
IL-12p40, IL-4, IL-23 and IL-10 were determined using a sandwich ELISA 
with antibody pairs from BD Pharmingen.  In 96-well enzyme immunoassay 
plates (GIBCO-Costar), each well was coated with 50 µl of anti-murine antibody 
in 0.1 M NaHCO3, pH 8.2 (anti-IL-12 p40 for IL-12p40 and IL-23; 5 µg/ml) or in 
PBS (anti-IL-4 and anti-IL-10; 2 µg/ml) overnight at 4oC.  The wells of the plate 
were blocked with 150 µl of 3% BSA/0.05% Tween 20 in PBS (IL-12p40 and IL-
23) or 0.5% BSA/0.05% Tween 20 in PBS (IL-4, IL-10) and incubated for 1 hr.  
The culture supernatants or serial dilutions of cytokine standards were added 
and incubated for 1-2 hr, followed by biotinylated detection antibodies (2ug/ml, 
50ul) for 1 hr, and streptavidin-horseradish peroxidase (HRP) (1:1000 in 50ul) for 
30 min. The plates were washed between each addition.  The tetramethyl 
benzidine (TMB; Sigma) substrates were developed for 5-30 min; the reaction 
was stopped with 1 N sulfuric acid and read at 450 nm on an Emax microplate 
reader (Molecular Devices; Menlo Park, CA).  The concentrations of sample 
cytokines were calculated from standard curves that were done for each plate.  
The levels of IFN-γ and IL-12p70 in supernatants were measured using BD 
OptEIATM Sets (BD Pharmingen) according to the manufacturer instructions. 
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Cell-based ELISA 
 
Phosphorylation of p38, JNK and ERK1/2 were measured by Fast 
Activated Cell-Based ELISA kits from Active Motif (Carlsbad, CA).  Briefly, 96-
well culture plates were treated with 100 µl 10 µg/ml poly-L-Lysine for 30 min at 
37oC and then washed twice with PBS.  uninfected DCs or Lp-infected DCs were 
then seeded into 96-well plates with culture medium containing THC (6µM) for 
indicated time.  Cells were fixed by replacing the culture medium with 100 µl of 
8% formaldehyde in PBS.  After 20 min incubation at room temperature, plates 
were washed three times with wash buffer (PBS containing 0.1% Triton X-100).  
Cells were then incubated with quenching buffer (wash buffer containing 1% 
H2O2 and 0.1% Azide) to inactivate the cells endogenous peroxidase activation.  
After 20 min, cells were washed twice and incubated with antibody blocking 
buffer 100 µl for 1 hr and incubated overnight with primary antibody for phospho-
MAP kinase protein or total-MAP kinase at 4°C.  Next day, cells were washed 
three times incubated with horseradish peroxidase-conjugated secondary 
antibody for 1 hr at room temperature and washed three times with wash buffer 
and twice with PBS. Subsequently the cells were incubated with 100 µl 
developing solution for 2-20 min at room temperature; the reactions were 
stopped by adding 100 µl stop solution and absorbance was read on an Emax 
microplate reader (Molecular Devices).  Levels of MAP kinase activation were 
expressed as the ratios of phosphorylated MAP kinase to total MAP kinase. 
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Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
Total RNA was extracted from dendritic cell cultures by standard 
techniques using TriReagent (Sigma) and quantitated using RiboGreen RNA 
Quantitation Kit (Molecular Probes, Eugene, OR). The extracted RNA was 
treated with DNase using DNA-free kit from Ambion (Austin, TX).  1µg of total 
RNA were used for cDNA synthesis at 42oC for 45 min by priming with 0.5 µg 
oligo (dT)15 primer, 20 nmol each deoxynucleoside triphosphate, 0.5 U RNase 
inhibitor, and 15 U avian myeloblastosis virus reverse transcriptase (Promega, 
Madison, WI) in a total volume of 25 µl.  2 µl of the reverse transcriptase product 
was used for PCR, which was carried out in PCR buffer (TaKaRa, Fisher; 
Atlanta, GA) containing 250 µM dNTP, 1.0 µM each primer and 2.5 U Tag DNA 
polymerase (TaKaRa).  The primer pairs used were as follows: cannabinoid CB1 
receptor forward primer, 5'-TCACCACAGACCTCCTCCTCTAC-3'; reverse 
primer, 5'-CTCCTGCCGTCATCTTTTC-3' (149 bp product); cannabinoid CB2 
receptor forward primer, 5'-GTACATGATCCTGAGCAGTGG-3'; reverse primer 
5'-TGAACAGGTACGAGGGCTTTCT-3' (147 bp product); TRPV1 forward primer, 
5'-AATTTGGGATGTGGAGCAAG-3'; reverse primer, 5-
GATCCCCCGAGTATCCATTT-3' (176 bp product); β-actin forward primer, 5'-
GGGAATGGGTCAGAAGAACT-3'; reverse primer, 5'-
AGGTGTGGTGCCAGATCTTC-3' (133 bp product); Jagged1, forward primer, 5'-
AGAAGTCAGAGTTCAGAGGCGTCC-3', reverse primer, 5'-
AGTAGAAGGCTGTCACCAGCAAC-3' ( 113 bp product); Delta4, forward primer, 
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5'-AGGTGCCACTTCGGTTACACAG-3', reverse primer 5'-
CAATCACACACTCGTTCCTCTCTTC-3' (123 bp product); and β-actin, forward 
primer, 5'-ATGGATGACGATATCGCT-3', reverse primer, 5'-
ATGAGGTAGTCTGTCAGGT-3' (530 bp product). All PCR were performed in a 
Mastercycler (Eppendorf, Westbury, N.Y.) at 60oC for annealing. The number of 
cycles in each PCR was as follows:  CB1, CB2, TRPV1 and β-actin (133bp), 40 
cycles; Jagged1 and Delta4, 35 cycles; and β-actin (530bp), 28 cycles.  PCR 
products were analyzed on ethidium bromide-stained, 2% agarose gels.  RT-
negative amplifications were also done to control for contaminating genomic 
DNA. 
 
Animal injections and tissue sampling 
 
Mice were immunized iv with 0.3-0.5 x 106 treated DCs suspended in PBS, 
and 7-9 days later spleens were isolated from mice.  Single-cell suspensions of 
splenocytes (2 x 106 cells/ml) were cultured with formalin-killed Lp (107/ml) for 24 
hr and supernatants collected for cytokine detection.  Or, DC-treated mice were 
challenged iv with live Lp (sublethal dose, 7 x 106) diluted in pyrogen free saline.  
Spleens were obtained after 24 hr and CFUs of Lp were counted.   In other 
experiments, mice were immunized iv with DCs (0.5 x 106) for two or three times 
at 7 day interval, challenged iv with a lethal dose of Lp (1.7-2.0 x 107) and 
survival of mice was monitored.   
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Statistical analysis 
 
Data were analyzed by one-way analysis of variance with Dunnett’s test 
for comparing individuals using SigmaStat (Jandel Scientific, San Rafael, CA), or 
using the two-tailed Student’s t test.  A value of p < 0.05 was accepted as 
indicating significance.   
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RESULTS 
 
 
Aim 1. To determine the effect of cannabinoids on the polarizing phenotype 
of DCs infected with Lp 
 
Lp infection of DCs induced IL-12p40 production 
 
IL-12 is a heterodimer produced by DCs and formed by the association of 
a 35-kDa light chain (p35) and a 40-kDa heavy chain (p40).  Interestingly, 
microbial components alone seem to induce primarily p40 with relatively low 
amounts of IL-12p70 (28).  Based on this, the kinetics of the IL-12p40 subunit 
production was investigated to determine the bone marrow-derived dendritic cell 
response to Lp infection.  Dendritic cell cultures were infected, supernatants 
harvested at indicated time points, and supernatant IL-12p40 was measured by 
ELISA.  As shown in Figure 2, there was a rapid increase in the secretion of the 
p40 protein reaching a peak by 44 hr following infection.  These data indicate that 
cultured bone marrow-derived DCs produce IL-12p40 following infection with 
Legionella.  
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Suppression by THC of Lp-induced IL-12p40 secretion 
 
To determine if cannabinoids can modulate the ability of DCs to produce 
IL-12p40, infected DCs were treated with increasing concentrations of THC (0, 1, 
3, 6 and 10 µM) and incubated for 24 hr followed by IL-12p40 measurements.  
Figure 3 A shows that THC treatment led to a significant decrease in IL-12p40 at 
a concentration of 3 µM and higher while drug vehicle (DMSO) had no effect.  In 
addition, Figure 3 B shows that the THC (10µM) suppression effect on DC IL-
12p40 was observed as early as 6 hr after treatment and Lp infection.  These 
data demonstrated THC consistently and significantly suppressed DC secretion 
of IL-12p40.   
 
No suppressive effect by THC on LPS-induced IL-12p40 production 
 
To examine if the THC effect is related to TLR4 signaling, we used LPS, a 
ligand for TLR4, as a stimulant in DC cultures.  Compared with Lp infection, LPS 
induced a rapid increase in IL-12p40 (Figure 4 A) that reached maximum at 12 hr 
after stimulation.  However, unlike with Lp infection, THC treatment had no 
significant effect on LPS-induced IL-12p40 production (Figure 4 B).  These data 
suggest that Lp infection stimulates IL-12p40 through receptors other than TLR4 
and that the THC suppressive effect is not generalized for all stimuli but selective 
for mechanisms related to Lp infection rather than the TLR4/LPS pathway.   
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Other non-selective agonists suppressed IL-12p40 production 
 
In addition to the effect of THC on DC function, we also examined the 
effect of the endocannabinoids 2-AG and Virodhamine.  2-AG has been shown to 
be produced in DC cultures (113) and Virodhamine has been reported in rat 
peripheral tissues including immune organs such as spleen in higher levels than 
AEA, another endocannabinoid (148).  2-AG and Virodhamine are potent 
agonists for both CB1 and CB2 (119, 148, 172) and there are no reports 
examining their functional effects on DCs.  We therefore treated Lp-infected DCs 
with various concentrations of 2-AG and Virodhamine.  We found that 2-AG 
treatment significantly suppressed IL-12p40 at concentrations of 1 µM and 10 µM 
(Figure 5 A).  No effect was observed with ethanol as the drug vehicle control.  
Virodhamine also showed significant suppression at 10 µM and the suppression 
level was comparable to 2-AG, though not as strong as THC used at the same 
concentration (Figure 5 B).  In addition, we tested other endogenous ligands, 
such as NADA and DEA, that are both CB1 selectvie and produced in nervous 
tissues (12, 16, 36, 61, 73).  We also tested the synthetic cannabinoids including 
the CB1 selective agonists ACEA, AJA, M-AEA (1, 46, 64, 80), and the CB2 
agonist JWH-133 (74).   The results showed these agents did not significantly 
suppress IL-12p40 in Lp infected DCs (data not shown).  Thus, nonselective 
cannabinoid receptor agonists, including THC, 2-AG and Virodhamine, but not 
other agonists, led to a significant inhibition of IL-12p40 production in our culture 
system.   
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THC suppressed the expression of DC maturation and polarizing markers 
 
Upon exposure to microbes, DCs are activated to go through a maturation 
process characterized by an increase in surface expression of MHC class II 
proteins and co-stimulatory molecules contributing to initiation of an effective 
adaptive immune response (76).  To determine if THC modulates this polarizing 
DC phenotype, we treated infected and non-infected DCs with either DMSO or 
THC and assessed the expression of these surface markers.  After 48 hr, we 
observed by flow cytometry that Lp infection increased the surface expression of 
CD86 and CD40; however, THC treatment significantly suppressed the 
expression of both markers (Figure 6 and Table 1).  Regarding MHC class II, we 
observed that although expression was high in all three groups, the intensity per 
cell of the marker was enhanced in the Lp infected-DCs but was significantly 
decreased by THC treatment (Table 1).  From these results, it is possible that 
drug suppression of T helper polarization is due in part to a down-modulation of 
these phenotypic markers. Other surface proteins such as Notch receptors are 
known to regulate T cell development (151).   Recently it was shown that the 
Notch ligands, Delta4 or Jagged1 on DCs promote induction of either Th1 or Th2 
activity, respectively (6).  We, therefore, examined the relative mRNA expression 
of these ligands in DCs loaded with Lp and treated with THC or vehicle for 18 hr.  
We observed that mRNA for both ligands was increased in DCs after Lp infection 
(LpDC/DMSO group; Figure 7) but that the Delta 4 band intensity relative to β-
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actin was decreased following THC treatment suggesting that the message level 
of this Th1 polarizing ligand was decreased by drug treatment.   
 
THC treatment did not affect Lp survival in DCs or enhance apoptosis of 
infected DCs 
 
THC has been observed to induce apoptosis in macrophages and 
lymphocytes (193) and also in DCs (43); therefore, it could be argued that drug 
suppression of IL-12 production and marker expression could be due to a toxic 
effect on DCs. Also, antigen presentation to CD4 T cells by DCs requires 
internalization and procession of infectious agents by the DCs and drug-induced 
suppression of phagocytosis, therefore, might contribute to suppression of T cell 
activation.  In order to test the THC effect on these other relevant DC functions, 
we studied the drug effect on the survival of Lp in DCs and the induction of 
apoptosis in Lp-infected DCs.  DCs were infected with Lp for 30 min followed by 
washing to remove non-internalized bacteria.  Infected cultures were then treated 
with THC or DMSO for 0, 24 and 48 hr and the number of cell-associated CFUs, 
as a measure of phagocytized bacteria, was determined by cell lysis and viable 
bacteria colony counts.  The results (Figure 8) showed that the bacteria 
internalizing function as measured by intracellular survival was unaffected by 
THC treatment.   Both drug-treated and vehicle treated cells restricted the growth 
of Lp in an equivalent manner over time. To determine if THC induced apoptosis 
in Lp-infected DCs, staining with propidium iodide and annexin V in treated DCs 
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was analyzed by flow cytometry.  Compared with uninfected DCs, the percentage 
of apoptotic cells, assessed as single positive for annexin V, was enhanced after 
Lp infection (Figure 9), and treatment with THC did not increase the annexin 
positivity. Furthermore, analysis of propidium iodide staining, as indicative of 
necrotic cells, was similar in infected and infected plus THC treated cells.  The 
data suggest THC treatment did not affect the degree of apoptosis or processing 
of bacteria in DCs following Lp infection.    
 
Aim 2. To determine the role of cannabinoid receptors in drug effects on 
DC polarization 
 
 
Expression of cannabinoid and vanilloid receptor mRNA in DCs 
 
The cannabinoid receptors identified so far are CB1 and CB2.  Both have 
been reported to be involved in the THC-induced attenuation of IL-12 production 
in drug-treated mice infected with Legionella (89).  Moreover, TRPV1, has 
recently been shown to bind AEA and other endocannabinoids and mediate their 
effects (96, 180, 196).  To examine receptor expression in dendritic cell cultures, 
RNA was isolated from DCs and analyzed by RT-PCR for CB1, CB2, and TRPV1 
messages.  Figure 10 shows mRNA of both cannabinoid receptors and TRPV1 
was readily detected in DCs and the level of cannabinoid CB2 receptor and 
TRPV1 messages appeared to be more abundant than CB1 receptor (Ratios of 
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target genes to β-actin are:  CB2 receptor 0.76, TRPV1 0.84, and CB1 receptor 
0.48). 
 
Pertussis toxin attenuated THC-induced suppression of IL-12p40 
 
Cannabinoid receptors are Gi protein-coupled receptors.  Gi signaling is 
suppressed by pertussis toxin and the toxin has also been reported to suppress 
IL-12 production  (19, 89).  To examine if THC -induced suppression of IL-12p40 
is through Gi protein-coupled mechanisms, DCs were pretreated with different 
concentrations of pertussis toxin (0.01, 0.1, or 1.0 ng/ml) for 18 hr followed by Lp 
infection and THC (3, 6 or10 µM) treatment for 24 hr.  Pertussis toxin (at 1.0 
ng/ml) completely reversed the suppression effect of THC at low concentrations 
(3 or 6 µM) (Figure 11).  However, the effect of THC at a higher concentration (10 
µM) was only partially attenuated by pertussis toxin (Figure 11).  This finding 
suggests the involvement of Gi protein-coupled mechanisms in the suppression 
of IL-12p40 at low THC concentrations, but other suppressive mechanisms at 
higher concentrations. 
 
Role of cannabinoid receptors in THC-induced suppression of IL-12p40 
 
To fully examine if cannabinoid receptors were involved in suppression of 
IL-12p40, experiments were performed using CB1-/- (194) and CB2-/- (23) mice.  
Because the knockout mice are on the C57BL/6 background and our previous 
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studies had been done with BALB/c mice, we first tested the response of bone 
marrow-derived DCs from wild-type C57BL/6 mice in terms of IL-12p40 production 
and suppression by THC.  Comparing Figure 12 A, to Figure 3 A shows that cells 
from C57BL/6 mice displayed a comparable suppressive response to those from 
BALB/c.  We next studied the response of DCs from CB1-/- and CB2-/- mice and the 
results showed that both were suppressed by THC similar to wild-type cells 
(Figure 12, panels B and C).  Since THC is a non-selective receptor agonist and 
can bind both CB1 and CB2 receptors (51), it is possible that the drug could have a 
relatively unimpeded effect in cells from single receptor knockout mice. To 
examine this possibility, the specific antagonists for CB1 (SR141716A) and CB2 
(SR144528) were used in combination with cells from knockout mice. CB1-/- DCs, 
after Lp addition, were pretreated with SR144528 at different concentrations for 
30 min prior to THC treatment and the reciprocal experiment was performed using 
CB2-/- and SR141716A pretreatment. After 24 h, supernatant IL-12p40 was 
assessed by ELISA. As a control, cultures were treated with either SR141716A or 
SR144528 only followed by infection and no effect on IL-12p40 was observed (not 
shown).  Table 2, shows the SR compounds attenuated the THC effect in 
knockout mice, especially at the lower drug concentrations.  For example, the 
attenuating effect of SR144528 (at 0.1 µM) in CB1-/- cells is nearly 70% of control 
at 3 µM THC but only 28% of control at 10 µM THC.  A higher concentration of 
SR144528 (0.5 µM) had the identical attenuating effect (data not shown). Similar 
decreases in receptor antagonist efficacy with increasing receptor agonist 
concentration were seen using CB2 -/- cells (Table 2). These results suggest that 
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cannabinoid receptors are involved in the THC-induced suppression of p40, 
especially at the lower drug concentrations, but that other mechanisms become 
involved as the THC concentration is increased.  
 
TRPV1 was not involved in THC effect 
 
From the above, it appears that mechanisms other than cannabinoid 
receptors are involved in THC suppression of IL-12p40.  Therefore, we tested for 
a possible role of TRPV1 in the THC effect by pre-treating with capsazepine, the 
specific receptor antagonist for TRPV1.  Dendritic cell cultures were infected with 
Lp and treated with either THC alone (3 and 10 µM) or in combination with 
capsazepine at 0.01, 0.1, and 1.0 μM.  As shown in Figure 13, there was no 
attenuating effect of capsazepine on the THC effect suggesting that TRPV1 
receptors were not involved in the response. 
 
The activation of p38 MAP kinase was modulated by THC 
 
It is reported that MAP kinases can be activated in response to ligands for 
G protein-coupled receptors, and many studies have indicated kinase activation 
affects either positively or negatively IL-12 production (18, 179, 186).  There are 
three major groups of MAP kinases in mammalian cells: the extracellular signal-
regulated protein kinases (ERK), the p38 MAP kinases, and the c-Jun-NH2-
terminal kinases (JNK)(44).  Many studies have suggested the modulation effect 
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of various cannabinoids on MAP kinase activity (69).  However, a role for these 
kinases in the THC effect on DC cytokine production has not been reported 
(158); therefore we examined the role of kinase activity in our system.  Initially we 
treated Lp-infected DCs with specific antagonists for different kinases for 18 hr 
and then measured IL-12p40.  We found that only the p38 inhibitor, SB203580, 
but not Erk inhibitor, UO128, nor JNK inhibitor, SP600125, was able to suppress 
IL-12p40 production suggesting only p38 kinase activation is required for Lp-
induced IL-12p40 secretion (Figure 14).  From this finding, we next examined the 
effect of THC on p38 activation in DCs during Lp infection.  As shown in Figure 
15, Lp infection induced an increase in phosphorylated p38 protein within 10 min 
after infection indicating an up-regulation in p38 activity.  THC treatment, 
interestingly, initially increased phosphorylated p38 but then caused a drop in the 
level by 3 hr after infection.  From these studies it is clear that p38 kinase is an 
important signaling component of the Lp induction of IL-12p40 and that 
modulation of p38 phosphorylation by THC might be a critical mechanism of drug 
action.   
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Aim 3. To determine the effect of THC treatment on the T helper polarizing 
function of DCs 
 
THC treatment impaired the immunization potential of Lp-loaded DCs 
 
Due to the pivotal role in stimulating T cells, DCs loaded with specific 
antigens have been utilized as immunizing vehicles in numerous studies of  
tumor therapies (29, 195) and infectious diseases (126).  To test whether DCs 
loaded with Lp would induce a specific immune response and if THC would 
impair this ability, we treated Lp-infected DCs in culture with 10 µM THC 
(LpDC/THC) or drug vehicle DMSO (LpDC/DMSO) for 24 hr.  DCs without 
infection and drug treatment were incubated for the same time as controls.  
Following treatment, DCs were injected iv into mice two to three times at 7 day 
intervals, and seven days after the last injection, the mice were challenged with a 
lethal dose (1.7-2.0x107) of bacteria and survival monitored. The results in Figure 
16 showed that uninfected DCs failed to induce protection as none of the mice 
survived; however, Lp-loaded DCs (LpDC/DMSO) induced significant protection 
with a survival ratio of 66 percent (6/9).  However, mice receiving loaded DCs 
treated with THC (LpDC/THC) showed no survival after 25 hr indicating a lack of 
immunizing potential similar to mice injected with non-loaded DCs.  In other 
experiments to examine immunizing potential, mice were injected with DCs, 
LpDC/DMSO or LpDC/THC (0.3-0.5x106) and seven to nine days later 
challenged with a sublethal dose (7x106) of Lp rather than a lethal dose as in the 
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above experiments.  After 24 hr, spleens were isolated and homogenized, and 
bacterial burdens measured by CFU analysis.  The data showed that spleens 
from mice receiving Lp-loaded DCs had much lower CFUs than spleens from 
mice receiving either unloaded DCs or loaded DCs treated with THC (Figure 17).  
These findings together demonstrated that mice immunized with Lp-loaded DCs 
were able to induce immunization against Lp infection and that THC treatment 
significantly attenuated this effect.   
 
THC treatment of Lp-loaded DCs inhibited Th1 activity in splenocytes from 
recipient mice 
 
Type 1 cytokines, including IL-12 and IFN-γ, can be measured in immune 
organs and are a measure of the development of protective immunity against 
intracellular microbial infections (150).  To determine polarization toward Th1 
immunity, the cytokine profiles in splenocytes of mice immunized with the various 
DC populations were analyzed to determine whether THC treatment of DCs 
suppressed an upregulation of Th1 activity in recipient mice.  As in the transfer 
experiments above, mice were immunized with DCs only, Lp-loaded DCs, or 
loaded DCs treated with THC, and seven to nine days later splenocytes were 
harvested from the recipient mice and stimulated in vitro for 24 hr with specific Lp 
antigens.  Supernatants from these cultures were collected and analyzed for 
type1-associated cytokines by ELISA.  As shown in Figure 18, the splenocytes 
from mice receiving Lp-loaded DCs treated with DMSO produced 1.5-2 fold 
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increases in IL-12p40 and IFN-γ as compared to splenocytes from mice treated 
with unloaded DCs. This suggested an upregulation of Th1 activity in the spleens 
of mice immunized with Lp-loaded DCs accounting for their enhanced resistance 
to Lp infection (see Figure 16 and 17).  However, THC treatment of the DCs 
inhibited this upregulation of Th1 activity, suggesting an attenuation of the 
immunizing potential of these cells (Figure 18 A and B).  IL-4 production by 
splenocytes was also examined and we observed it was suppressed following 
injection of Lp-loaded DCs either treated or not with THC (Figure 18 C).  This 
suggested that the increase in Th1 activity in the spleens coincided with a 
decrease in the Th2 cytokine, IL-4; furthermore, it suggested that THC 
suppressed Th1 cytokines by mechanisms other than the upregulation of IL-4. 
The data overall suggested that THC treatment of antigen-loaded DCs can 
suppress the immunizing and Th1 polarizing potential of these cells when 
subsequently injected into mice.  
 
IL-12p40 addition restored the polarizing function of THC-treated DCs 
 
We have shown above that THC suppresses the production of IL-12p40 in 
Lp-infected DC cultures.  Therefore, to examine if this attenuation is responsible 
for the impaired Th1 polarizing function of these cells, co-cultures of DCs with T 
cells from both unprimed and Lp-primed animals were prepared to examine the 
reconstitution efficacy of exogenously added IL-12p40.  Figure19 A shows results 
from co-cultures of Lp-loaded DCs and unprimed CD4 T cells.  Lp loading of DCs 
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induces the production of IL-12p40 as detected in culture supernatants by ELISA 
and THC treatment of the cells suppressed this response.  The addition of 
unprimed T cells had little effect on IL-12 production (Figure 19 A) and in studies 
not shown, no IFN-γ was detected in these cultures.  We next examined the 
accessory cell potential of drug treated DCs in cultures containing Lp-primed T 
cells and supplied with various concentrations of IL-12p40.  Figure 19 B shows 
that DCs plus primed T cells (LpCD4) produced a relatively small amount of IL-
12p40; however, when DCs were loaded with Lp (LpDC/DMSO), a robust IL-
12p40 response was evident and this was significantly attenuated by THC 
treatment (LpDC/THC + LpCD4).  Of interest was the finding that the addition of 
recombinant IL-12p40 protein to the cultures increased the IL-12 supernatant 
concentrations above the amounts added (Figure 19 B).  For example, addition 
of 0.5ng/ml recombinant IL-12p40 resulted in an increase of supernatant IL-12 
from 2ng to 6ng/ml. Furthermore, in contrast to co-cultures containing unprimed 
CD4 T cells, cultures containing primed T cells, produced in addition to IL-12p40,  
robust amounts of IFN-γ but only in the presence of Lp-loaded DCs (Figure 19 C) 
and this effect was attenuated by THC treatment of the DCs.  However, the 
addition of recombinant IL-12p40 completely restored IFN-γ production 
suggesting a restoration of Th1 polarization by IL-12.  In addition to IL-12p40, we 
also tested for the presence of IL-12p70, IL-23, and IL-10 in the culture 
supernatants.  These cytokines were not detected suggesting that the 
suppression of IL-12p40 by THC treatment was primarily responsible for the 
reduced Th1 polarization.  
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Figure 1.  THC suppressed the production of IL-12p40 and IL-6 in bone 
marrow-derived DCs.  L. pneumophila (Lp) infected DCs were treated with 
DMSO (Lp), or THC 6 µM for 24 hr.  Supernatants were collected for cytokines 
detection.  Data represent the mean of 3 experiments ± S.E.M..  *P< 0.05, 
compared to Lp group.   
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Figure 2.  Lp infection induced IL-12p40 production in bone marrow-derived 
DCs from BALB/c mice.  Immature bone marrow-derived DCs were infected as 
indicated in the methods.  Supernatants were collected at indicated time points 
and IL-12p40 measured by ELISA. Data represent the mean of 4 experiments ± 
S.E.M..   
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Figure 3.  THC, in a concentration-dependent manner, suppressed IL-12p40 
production in Lp-infected BM-DCs from BALB/c mice.  (A) Lp-infected BM-
DCs were treated with different concentrations of THC or the highest 
concentration of DMSO (vehicle control) for 24 hr. (B) Using THC at 10μM, THC 
suppresses IL-12p40 production at 6, 12, and 21 hr.  Data represent the mean of 
3-5 experiments ± S.E.M.. *P< 0.05, compared to Lp group (THC 0 µM).   
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Figure 4.  No significant effect of THC on LPS-induced IL-12p40 from DCs.  
(A) immature BM-DCs were incubated with LPS (1 µg/ml).  Supernatants were 
collected at indicated time points and IL-12p40 measured by ELISA.  (B) DCs 
were stimulated with LPS (10 ng/ml) and treated with different concentrations of 
THC or the highest concentration of DMSO (vehicle control) for 24 hr. 
 46
 
  A                                                               B                    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Cannabinoid receptor agonists 2-AG and Virodhamine in a 
concentration-dependent manner, suppressed IL-12p40 production in Lp-
infected bone marrow-derived DCs from BALB/c mice.  Lp-infected DCs were 
treated with different concentrations of 2-AG or the highest concentration of 
Ethanol (ETOH, vehicle control) (A) or Virodhamine with different concentrations 
or THC or 2-AG at 10 µM (B) for 24 hr.  IL-12p40 was detected by ELISA and the 
data represent the mean of 3-5 experiments ± S.E.M..  *P< 0.05, compared to 2-
AG 0 µM (A) or Virodhamine 0 µM (B). 
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Figure 6.  THC suppressed the expression of maturation markers on Lp 
infected-DCs.  Cell surface markers were determined by flow cytometry on DCs 
treated for 48 hr in various ways: uninfected (DC); Lp-infected and DMSO treated 
(LpDC/DMSO); and Lp-infected and THC (10 µM) treated (LpDC/THC).  Data are 
expressed as percent expression (%) of the surface marker and mean 
fluorescence intensity (MFI) of the population for the marker.  Data are 
representative of 4 experiments.  
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Table 1.  THC treatment suppressed DC maturation markers.  Cell surface 
markers were determined in uninfected DCs (DC), Lp-infected and DMSO 
treated cells (LpDC/DMSO) or THC (10 µM) treated cells (LpDC/THC) by flow 
cytometry after 48 hr treatment.   
 
Percent Expression 
 
 
 
 
 
 
Fluorescent intensity per cell  
 
 
 
 
                                
a = Percent +/- SEM,   n=4  
b =Mean fluorescence intensity +/- SEM; n=4  
# = p <0.05 versus the uninfected DC control 
* = p <0.05 versus LpDC/DMSO group    
MHC class II     2212.1 ± 499.5 b     2693.7 ± 313.1          1433.5 ± 348.6* 
CD86                 147.1 ± 8.6             183.7 ± 22.1               133.2 ± 12.7  
CD40                   83.4 ± 21.4             130.3 ± 29.6                81.0 ± 9.2    
                                       DC                  LpDC/DMSO              LpDC/ THC 
MHC class II     82.3 ± 11.2a         87.2 ± 6.0                  79.4 ± 4.8               
CD86                 63.8 ± 3.1            81.7 ± 2.8#                  53.7 ± 5.4* 
CD40                  37.7 ± 7.9             70.1 ± 5.6#                 36.5 ± 9.6* 
                                 DC                  LpDC/DMSO              LpDC/ THC 
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Figure 7.  THC suppressed the expression of Delta 4 in Lp-infected DCs 
(LpDC/THC) as compared to infected DCs treated with DMSO 
(LpDC/DMSO).  DCs were uninfected or infected with Lp and treated with DMSO 
or THC (10 µM) for 18 hr.  Jagged1, Delta4, and β-actin mRNAs were amplified 
by RT-PCR.  Data are representative of 3 experiments.   
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Figure 8.  Lp uptake and survival were not affected by THC treatment of Lp 
infected-DCs.  DCs infected with Lp for 30 min, washed twice to remove non-
internalized bacteria and treated with DMSO or THC (10 µM) for 0, 24, 48 hr.  At 
various time post-infection, cell lysates were harvested and plated on agar 
medium, and CFUs of Lp determined by plate counts at 72 hr.  Data represent 
the mean of 3 experiments +/- SEM. 
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Figure 9.  Apoptosis and cell death were not affected by THC treatment.  
Cultures of DCs were untreated (DC) or treated for 24 hr with either DMSO 
(LpDC/DMSO) or THC at 10 µM (LpDC/THC) and apoptosis and cell death were 
analyzed by staining with Annexin V and propidium iodide, respectively.   (A) Dot 
plot of propidium iodide and Annexin V staining; representative of 3 similar 
experiments. (B) Percent of apoptotic cells (Annexin V+; propidium iodide-) and 
dead cells (propidium iodide+); mean +/- SEM , n=3. #, p <0.05 versus DC 
control.  
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Figure 10.  Demonstration by RT-PCR of cannabinoid receptor, TRPV1 and 
β-actin message in RNA from bone marrow-derived DCs.  Negative RT 
represents PCR results when the reverse transcriptase is left out of reaction mix. 
 
200 bp 
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Figure 11.  Pertussis toxin, the Gi signaling inhibitor, attenuated the 
suppression effect of THC on IL-12p40.  Bone marrow-derived DCs were 
preincubated with pertussis toxin at 0.01, 0.1, 1.0 ng/ml 18 hr prior to Lp infection 
and treated with THC 0, 3, 6 and 10 µM.  Cells were incubated for 24 hr and data 
represent the mean of 3 experiments ± S.E.M.. *P< 0.05, compared to THC + Lp 
group.   
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Figure 12.  THC suppressed IL-12p40 production in Lp-infected bone 
marrow-derived DCs from C57BL/6 mice. (A) THC suppresses IL-12p40 in 
DCs from wild type (WT) mice.  (B and C)  THC suppresses IL-12p40 in 
cannabinoid CB1 receptor knockout (CB1-/-) and CB2 receptor knockout (CB2-/-) 
mice.  Lp-infected DCs were treated with different concentrations of THC or the 
highest concentration of DMSO (vehicle control).  Cells were cultured for 24 hr.  
Data represent the mean of 3 experiments ± S.E.M..  *P< 0.05, compared to 
THC 0 µM.   
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Table 2.  Attenuation effect of SR compounds on THC-induced suppression 
of IL-12p40 in Lp-infected bone marrow-derived DCs from cannabinoid 
receptor knockout mice.  Lp-infected DCs were pretreated with SR144528 
(CB1-/- DCs) or SR141716A (CB2-/-  DCs) at 0.01, 0.05, or 0.1 µM for 30 min prior 
to THC (3, 6 or 10 µM).  Cells were cultured for 24 hr and the data represent the 
mean of 4 experiments ± S.E.M..  SR alone at these doses had no effect on IL-
12p40 production (not shown).  The percentage of attenuation is computed from 
1-[IL-12p40(Lp-SR/THC/Lp)/Lp]/[IL-12p40(Lp-THC/Lp)/Lp]. 
 
 
 
 
 
 
 
 
 
 
SR144528                   Attenuation (%) 
(µM)           
0.01        20.0 ± 6.0      18.2 ± 8.8      8.4 ± 1.5   
  
0.05        59.5 ± 8.7      37.0 ± 5.7      15.8 ± 5.0  
                                  
0.1          69.6 ± 7.0      44.7 ± 2.5      27.9 ± 2.0  
THC (µM)        3                  6                  10  
CB1-/-  
SR141716A                 Attenuation (%)          
(µM)         
0.01        24.1 ± 7.8      18.9 ± 4.2      3.0 ± 1.6   
 
0.05        38.0 ± 5.1      33.2 ± 4.1      14.7 ± 5.8 
                                   
0.1          61.1 ± 8.5      39.9 ± 7.0      24.2 ± 5.7  
THC (µM)        3                  6                  10  
CB2-/-  
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Figure 13.  Vanilloid receptor inhibitor Capsazepine did not antagonize the 
suppression effect of THC on IL-12p40.  Lp-infected DCs were pretreated with 
Capsazepine at 0.01, 0.1 and 1 µM for 30 min prior to THC (3 or 10 µM).  Cells 
were cultured for 24 hr and the data represent the mean of 3 experiments ± 
S.E.M..   
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Figure 14.  p38 MAP kinase, but not JNK or ERK was required for IL-12p40 
production in Lp-infected DCs.  Lp-infected DCs were treated with ERK 
inhibitor UO126 (5 µM), or JNK inhibitor SP600125 (5 µM) or p38 inhibitor 
SB203580 (5 µM) for 18 hr.  IL-12p40 in supernatants was detected by ELISA 
and the data represent the mean of 3 experiments ± S.E.M..  *P< 0.05, compared 
to Lp group. 
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Figure 15.  THC modulated p38 MAP kinase activation.  DCs were either 
uninfected or infected with Lp or treated with THC (6 µM) following infection.  
Cells were fixed at indicated time points and the levels of p38 kinase expression 
were measured by cell-based ELISA.  Data are expressed as the ratio of 
phosphorylated p38 to total p38 in DCs.  Data represent the mean of 3 
experiments ± S.E.M.. *P< 0.05, compared to Lp group.   
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Figure 16.  THC impaired immunization potential of Lp-loaded DCs.  Naïve 
mice were iv immunized with DCs (0.5x106 cells/mouse) two to three times at 7 
day intervals prior to being challenged with a lethal dose of Lp (1.7 - 2.0 
x107/mouse).  The DCs were either not loaded with Lp (DC group) or loaded with 
Lp and treated for 24 hr with either DMSO (LpDC/DMSO group) or THC, 10 µM 
(LpDC/THC group).  Mice were monitored for survival and the data represent 9 
mice per group from 3 experiments.   
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Figure 17.  THC treatment of Lp-loaded DCs inhibited immunizing potential 
as evidenced by increased bacterial burden.  Mice were iv injected with 0.3-
0.5x106 DCs loaded or not in vitro with Lp and treated with DMSO 
(LpDC/DMSO), or THC at 10 µM (LpDC/THC) for 24 hr.  Then, mice were 
challenged 7-9 days later with a sublethal dose of Lp (7x106  Lp/mouse),  
spleens isolated 24 hr post-infection, and colonies forming units (CFU) 
determined by plate counts.  Data presented as the mean CFU +/- SEM for 4 
mice per group.  # and * (p <0.05) versus the uninfected DC control and 
LpDC/DMSO group, respectively. 
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Figure 18.  THC treatment of Lp-loaded DCs inhibited the expression of Th1 
cytokines in splenocytes from immunized mice.  Mice were iv injected with 
control DCs (0.3-0.5x106), Lp-loaded and DMSO treated DCs (LpDC/DMSO), 
and Lp-loaded and THC treated DCs (LpDC/THC) as in Figure17. Seven to 9 
days post-injection, splenocytes were harvested and stimulated in vitro with killed 
Lp (107/ml) for 24 hr and cytokines (IL-12p40, IFN-gamma and IL-4) detected in 
supernatants by ELISAs (A, B and C).   Data represent the mean of 5 
experiments +/- SEM.  # and * (p <0.05) versus the control DC and Lp/DMSO 
group, respectively. 
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Figure 19.  THC suppression of DC IL-12p40 production mediated loss of 
Th1 polarization of Lp-primed  CD4+ T cells.  Cytokines were measured in 24 
hr supernatants of co-cultures containing DCs and either Lp-primed or unprimed 
CD4 T cells. Primed T cells were obtained 5 days post-infection from the spleens 
of mice infected with a sublethal dose of Lp.  (A) IL-12p40 measured in co-
cultures containing Lp-loaded DCs treated with DMSO or THC (10 µM) (LpDC/ 
DMSO or LpDC/THC) co-cultured with unprimed CD4 T cells.  (B) IL-12p40 
measured in co-cultures treated as in panel A and containing primed T cells; 
recombinant IL-12p40 was added in increasing amounts.  (C) IFN-gamma 
measured in co-cultures as in panel B and treated with IL-12p40. Data are 
representative of 4 experiments.  
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Figure 20.  THC suppresses Th1 activation signals.  Signals delivered by DCs 
are required for Th1 activation (2, 152).  THC suppressed Th1 immune response 
is associated with THC impaired DC function leading to the insufficiency of 
(pointed by dot arrows):  
1. Polarizing signals including suppressed IL-12p40 production and Notch ligand 
Delta 4 expression; 
2. Antigen-specific signal through suppressed MHC class II expression; 
3. Co-stimulatory signal as low expression of CD86 and CD40. 
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Figure 21.  Postulated signaling pathways involved in THC suppression 
effect on DCs.  Lp infection, through TLRs and activation of NF-kappaB and 
p38, leads to DC activation and maturation.  THC may suppress these effects via 
Gi/PI3K/AKT pathway and subsequent regulatory JNK activation; and PPAR 
stimulation to suppress NF-kappaB transactivation.  Normal arrow represents 
positive regulation; dot arrow represents negative regulation.      
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DISCUSSION 
 
DCs are potential targets of cannabinoids 
 
Cannabinoids, such as THC, have been shown to be immunosuppressive 
and anti-inflammatory (83) and can polarize adaptive immunity in mice away from 
Th1 immunity and toward Th2 immunity (89, 134).  Polarization by cannabinoids 
has recently been reviewed  (87, 158) and Th1 suppression occurs following 
treatment with endocannabinoids (112, 139), in drug-treated T cell cultures 
stimulated with allogenic DCs (191), following LPS and drug injection into C. 
parvum-primed mice (168), and in immune responses to tumor cells (192).  In at 
least one of these studies (168), cannabinoids were shown to suppress 
production of the DC cytokine, IL-12.  Because DCs are a primary link between 
innate and adaptive immunity, we postulated that DCs might be a target of 
cannabinoid action and that suppressing the function of these cells could be a 
key event in the drug-induced suppression of Th1 polarization.   
Intracellular bacterial pathogens can modulate the host cell intracellular 
meilu thus providing an environment supportive of intracellular growth and 
survival. Lp, for example, a microbe ubiquitous in the aquatic environments and 
the causative agent for Legionnaires’ disease in humans, can replicate within 
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eukaryotic host cells such as protozoa and human phagocytic and epithelial cells 
(68, 131).  It has been demonstrated that T helper cell cytokines such as the type 
1 cytokine IFN-γ can activate host cells to control Lp infection and other 
intracellular pathogens (25, 91, 130).  In vivo experiments have shown that Lp 
causes severe infection in IFN-γ-deficient mice and IFN-γ treatment results in 
increased clearance of the bacteria from the lungs (166).  Suppression of 
immunity to Lp in mice has also been reported by our group following injection of 
THC along with a decrease in Th1 acivity and associated cytokines such as IFN-
γ and IL-12 (88).  DCs are central in the orchestration of the formation of Th1 
immunity from naïve CD4+ by providing multiple signals after pathogen priming.  
One set of these signals is provided by members of the IL-12 family shown to 
play a pivotal polarizing role in Th1 differentiation (106, 138, 145).  IL-12p40 
protein, which is a subunit shared by two IL-12 family members, IL-12p70 and IL-
23,  has been shown to be indispensable in Th1 development either by 
combining with other subunits or on its own (31, 66, 147, 184).  
 
THC suppressed IL-12p40 production in Lp-infected DCs 
  
DCs are a major cell source of IL-12.  These cells can be purified from 
various mouse tissues such as spleen and bone marrow and studies with 
cultures of these cells have shown that a number of different bacteria induce IL-
12p40 (79).  We speculated that cultured DCs would also produce IL-12 in 
response to Lp infection since these bacteria have been shown to increase 
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serum levels of IL-12 in infected mice (89).   We also wanted to study dendritic 
cell cultures in order to see if THC added to the cultures directly suppressed IL-
12 production by these cells.  Initially, we observed (Figure 2) Lp infection of DC 
cultures triggered a high level of IL-12p40 production that was significantly 
inhibited by THC treatment in a concentration-dependent manner (Figure 3).  
Thus, it appears that Lp like other microbes directly induces DCs to produce IL-
12p40 (79).  Also, because DCs are a major source for serum IL-12 levels in 
infected animals, the current in vitro results suggest THC is suppressing DC 
function resulting in decreased serum IL-12 production in treated animals (89). 
 
THC did not suppress LPS-induced IL-12p40 secretion 
 
The immediate recognition of microbes by the innate immune system 
plays a crucial role in host defense (121).  This recognition process is based on 
the detection of unique pathogen-associated molecular patterns (PAMPs) by 
pattern recognition receptors of the host such as TLRs.  Activation of TLRs not 
only plays a critical role in activation of innate immunity but also in the activation 
of adaptive immune responses (120) through the production of IL-12p40 and 
other polarizing factors.  One of the most commonly studied TLRs is TLR4 and 
we found that the TLR4 agonist LPS induced a significant amount of IL-12p40 in 
our DC cultures, which is consistent with previous reports  (127). However, the 
LPS effect was not suppressed by THC as was the case with Lp infection (Figure 
4).  This finding is not surprising in light of recent studies showing that production 
 72
of IL-12p40 after infection with Lp was inhibited in macrophages from TLR2(-/-) 
but not inTLR4(-/-) mice suggesting that TLR2, but not TLR4, is involved in 
cytokine production by Lp (5).  Archer et al. also reported that TLR2 but not TLR4 
is involved in MyD88-dependent responses to Lp infection in mice (7).  Besides 
TLR2, other TLRs might be stimulated by Lp, such as TLR9, which recognizes 
bacterial unmethylated CpG motifs and has been shown to be involved in the IL-
12 response to Lp (135) and other bacteria such as Brucella abortus (72) and 
Mycobacterium tuberculosis (9).  Thus, our data suggests that the mechanism of 
THC suppression of IL-12p40 does not involve the signaling cascades 
associated with all of the TLRs, for example TLR4, but might be associated with 
others such as TLR2 and 9. 
 
THC suppressed DC maturation and polarizing molecules 
 
 Besides producing polarizing cytokines such as IL-12, DCs also promote  
the maturation of T helper cells by the production of helper cell-surface proteins 
such as MHC class II and co-stimulatory molecules (79).  To further explore the 
basis of THC modulation of DC function, we examined THC effects on the 
expression of these surface markers.  The results showed THC treatment 
markedly reduced the expression of MHC class II and the co-stimulatory 
molecules CD86 and CD40 (Figure 6 and Table 1).  The mechanism for this is 
unclear at this time; however, signaling through cannabinoid receptors could be 
involved because ligation of similar receptors (i.e., Gi-linked) has been shown to 
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modulate DC maturation from human PBMCs (33).  In addition to the above 
markers, Notch ligand expression on DCs has been reported to be critical for T 
cell differentiation and various stimuli have been shown to induce the expression 
of either Jagged1 (Th2 polarizing) or Delta4 (Th1 polarizing) (6).  Our data 
showed mRNAs for Jagged1 and Delta4 were induced in DCs after Lp infection; 
however, THC treatment significantly suppressed the expression of the Th1 
polarizing Delta4 ligand but had little effect on Jagged1 (Figure 7).  These 
results, coupled with our other findings that the THC-treated DCs are deficient in 
promoting Th1 polarizitation, support the previous conclusion that the Delta 
ligands induce Th1 cells (6).  The THC effect could involve cannabinoid receptors 
because G protein-coupled receptors activated through Gs have been shown to 
increase Jagged ligand expression and polarize to Th2 (6); therefore, 
cannabinoid receptors, coupled to Gi, might be expected to suppress Delta 
ligands and Th1 polarization as seen in our study along with inhibiting IL-12 as 
shown by others (95). 
 
THC did not affect Lp survival and apoptosis in DCs 
 
To initiate T helper activation, DCs must in addition to producing cytokines 
and co-stimulatory molecules, take up and process the bacteria for pathogen-
related antigen presentation.  The cells must also survive the bacterial infection 
and we wanted to see if antigen uptake by and survival of DC was also affected 
by cannabinoids.  In contrast to macrophages, wherein intracellular growth of Lp 
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was observed (161), we observed that DCs restricted Lp growth with moderate 
killing over time (Figure 8).  THC-treated DCs showed a similar restriction and 
time course of intracellular infection, suggesting Lp handling was the same in 
both groups.  THC has been reported to induce apoptosis under certain 
conditions in mouse DCs (43) and Lp infection has also been shown to be 
apoptotic in macrophages and other cells (3, 53).  To see if these treatments 
together were adversely affecting DC survival, we examined necrosis and 
apoptosis induction.  Our results with Annexin V staining (Figure 9) showed that 
Lp infection induced limited apoptotic activity in DCs similar to that observed in 
other cell types (3, 53).  THC treatment did not increase the level of apoptosis 
and both treatments had no effect on cell necrosis as measured by propidium 
iodide staining (Figure 9).  The minimal effect of THC on apoptosis we observed 
is at variance with that observed previously.  We used the drug at 10 µM and this 
concentration was shown previously to induce Annexin V positivity in 80% of the 
cells (43).  However, the previous studies were done using serum-free medium 
while ours were done with medium containing fetal calf serum which is known to 
reduce the potency (and toxicity) of the added cannabinoids (90).  From these 
results, it is concluded that THC treatment is not suppressing T helper 
polarization by either altering the intracellular life cycle of Lp or by causing 
enhanced apoptosis and death of the DCs. 
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The involvement of cannabinoid receptors and MAP kinases in THC 
effect  
 
The previous studies showed that cannabinoid treatment of DCs altered 
the polarizing phenotype of the cells in terms of cytokine and co-stimulatory 
production.  To uncover the mechanism of these effects, we wanted to see if 
cannabinoid receptors might be involved.  One previouos report showed that CB1 
and CB2 mRNA and protein were expressed in human blood-derived DCs but the 
function of these receptors was not studied (113).  In the current study, we 
showed mRNA for both receptors was also expressed in mouse bone marrow-
derived DCs and that CB2 message appeared to be more abundant than CB1 in 
these cells (Figure 10).  Furthermore, using DCs from receptor knockout mice as 
well as using CB1 and CB2 antagonists, we observed that these receptors 
mediated suppression but only at the lowerTHC concentrations used in these 
studies (Figure 12 and Table 2).  CB1 and CB2 are Gi protein-coupled receptors 
and activate genes by means of the heterotrimeric G protein complex containing 
the α-GTP subunit and the βγ dimer (19). Stimulation of cannabinoid receptors 
with agonists has been shown to modulate various signaling and transcription 
factors; for example, cAMP (164) and AP1 and MAP kinase (50) were decreased 
in splenocytes following treatment with cannabinoids, and drug effects were 
attenuated by pertussis toxin which inactivates Gi (78).  In the current study, we 
showed that pertussis toxin treatment completely attenuated the effect of low 
THC concentrations; however, complete attenuation could not be achieved at 
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higher drug concentrations (Figure 11).  This finding along with the partial 
attenuation observed with cells from receptor knockout mice treated with receptor 
antagonists suggested that, at the low concentration of THC, the drug is 
suppressing cytokine production through activation of a Gi-coupled mechanism 
linked to both cannabinoid receptor and non-receptor pathways.  The Gi-coupled 
mechanism might involve the βγ dimer of the Gi that is reported to suppress IL-12 
through MAP kinases (19, 52).  Many studies have shown cannabinoids 
modulate the activation of MAP kinases (38).  These protein kinases are widely 
used throughout evolution in many physiological processes and are involved in 
all aspects of immune responses, including the regulation of naïve Th cells 
differentiation into Th1 or Th2 cells (167) and the production of IL-12 either 
directly or indirectly through production of Th2 type cytokines (103, 179, 189).  
MAP kinase activation and IL-12 production have been shown to be induced by 
G protein-coupled receptors in response to ligands such as bacterial toxins, 
neuropeptides and chemoattractants (19).   Our data showed that p38 MAP 
kinase, but not Erk or JNK, was involved in IL-12p40 production upon Lp 
infection (Figure 14). Furthemore, THC treatment enhanced p38 phosphorylation 
initially followed by suppression with time (Figure 15).  Recently, using human 
monocytes, MAP kinase phosphorylation was observed to accompany the 
inhibition of LPS/IFN-induced IL-12 production by the mediator C5a and this 
was shown to involve the PI3K/Akt signaling pathway (95).  Together, these data 
suggest THC and other Gi ligands suppress IL-12 through MAP kinase 
phosphorylation. 
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TRPV1 was not involved in THC effect 
 
Besides cannabinoid receptors, our data suggest that THC might also be 
working through other moieties (CBRX?) with affinity for THC but a relatively low 
sensitivity to cannabinoid receptor antagonist. For example, it has been reported 
that a non-CB1 G protein-coupled receptor in mouse brain was activated by AEA 
and WIN55212-2 but not other cannabinoid receptor agonists and was relatively 
insensitive to antagonism with SR141716A (20).  In addition, the attenuating 
activity of SR141716A on the antinociceptive effect of cannabinoids in mice was 
found to be receptor agonist-dependent (185), being most potent following 
CP55,940 injection and least potent following AEA injection.  Vanilloid receptors, 
such as TRPV1, might also be involved because they respond to 
endocannabinoid treatment but are relatively insensitive to SR141716A (96, 180, 
196).  There are no previous reports of TRPV1 expression in DCs and we are the 
first to show in the current study that DCs readily express TRPV1 mRNA (Figure 
10).  Because we could find no reports that THC activates TRPV1 receptors on 
immune cells, we tested the possibility that TRPV1 was mediating the 
suppression of IL-12p40 in our system.  DCs, pretreated with the selective 
TRPV1 antagonist, capsazepine, were still completely suppressed by THC 
treatment suggesting that TRPV1 was not involved in the drug effect on IL-12p40 
production (Figure 13). 
The above results show that Lp infection of bone marrow-derived DCs 
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leads to an increase in IL-12p40 and that co-treatment with THC significantly 
suppresses this effect.  We also showed that inhibition of Gi signaling completely 
attenuates the THC effect at low cannabinoid concentrations; however, inhibiting 
CB1 and CB2 at low doses only partially attenuates the THC effect and inhibition 
of TRPV1 has no effect.  These data suggest that THC is working through Gi 
signaling in DCs to suppress IL-12p40 and is also working partially through 
cannabinoid receptors in addition to possibly a third receptor with sensitivity to 
the effects of THC but low sensitivity to the action of SR compounds.  In addition, 
we found that besides THC, two endocannabinoids, 2-AG and Virodhamine had 
a significant suppression effect on IL-12p40 production from Lp-DCs (Figure 5) 
suggesting the possible involvement of endocannabinoids in host anti-
inflammatory responses.  Other cannabinoids, either endogenous or synthetic, 
however, did not seem to have significant effect on DC IL-12p40 production.  
These observations support the speculation that other targets besides CB1 and 
CB2 may exist and that other signaling mechanisms may be involved in different 
cannabinoid-mediated actions. 
 
THC impaired the immunization potential of Lp-loaded DCs 
 
  The results so far show that THC treatment can change the polarizing 
phenotype of DCs to one that is non-supportive of Th1 polarization.  To further 
examine the drug effects and to functionally test the polarizing potential of the 
DCs, we utilized a cellular immune reconstitution model of infection with Lp.  DCs 
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are potent antigen-presenting cells and loading them with microbial antigens has 
been shown to immunize mice against infection with various pathogens (104, 
171, 181).  In the current study, we showed that DCs loaded in vitro with Lp and 
injected into mice immunized and protected the mice to a subsequent lethal Lp 
infection (Figure 16).  Evidence of immunity to Lp was documented because the 
number of CFUs in the spleens of the animals was reduced after injection with 
Lp-loaded DCs (Figure 17).  Thus, it appears, that bone marrow-derived DCs 
have good immunizing potential when loaded or infected with Lp in culture and 
then injected into recipient mice.  The immunity generated was probably Th1 
because replication of Lp in the mice is known to depend on the activity of these 
helper cells (134).  The next question involved what effect THC treatment had on 
the immunizing potential of the loaded DCs.  These results showed that THC 
treatment attenuated the DC function as evidenced by the reduced ability to 
protect against infection and to reduce the number of CFUs in the spleens of 
infected mice (Figure 16 and 17). 
 
THC inhibited Th1 activity induced by Lp-loaded DCs  
 
  The above results suggested that THC treatment suppressed the Th1 
polarizing potential of Lp-loaded DCs.   To test this more directly, splenocytes 
from immunized mice were analyzed for Th1 and Th2 cytokine production in vitro 
in response to Lp antigens.  The results in Figure 18 showed that, as expected, 
immunization with Lp loaded DCs (LpDC/DMSO group) caused an increase in 
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the Th1 polarizing cytokines IL-12p40 and IFN-γ, probably produced by the 
antigen-presenting cells and lymphocytes in the splenocyte cultures; however, 
this effect was attenuated in splenocytes from animals immunized with THC-
treated DCs (LpDC/THC group), suggesting drug treatment suppressed their 
polarizing potential.  The mechanism surrounding the regulation of Th1 activity is 
controversial.  IL-4, a key cytokine in promoting Th2 cells (173), was originally 
proposed to also inhibit Th1 development; however, more recently this has been 
challenged and IL-4 has been shown to actually promote Th1 development by 
inducing DCs to produce IL-12 (15).  Because of these uncertainties and 
because we had previously observed a decrease in IL-12 and increase in IL-4 
production in THC-treated and Lp-infected mice (89), we examined for IL-4 
production by splenocytes from immunized mice.  Figure 18 shows that 
immunization suppressed IL-4 production; furthermore, immunization with THC-
treated cells had no effect on this suppression.  These findings suggest several 
things.  First, as expected, immunization by Lp led to a decrease in IL-4 
producing splenocytes as confirmation of Th1 polarization in response to this 
agent (134).  Second, it appears that immunization with drug-treated and Lp-
loaded DCs, causes a decrease in Th1 activity with no concomitant increase in 
Th2 activity, at least as measured by IL-4 producing splenocytes.  Third, these 
results would appear to be at odds with our previous finding that THC injection 
along with Lp infection led to an increase in IL-4.  However, there are a several 
differences in the two models and the increase in IL-4 observed in our previous 
study (89) occurred within hours after infection and was transient in nature 
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whereas, in the current study, IL-4 was measured in splenocytes taken 7 - 9 days 
following immunization.  Also, in the previous study, THC was injected into Lp-
infected mice, whereas in the current model, mice were immunized with THC-
treated and Lp-loaded DCs.  It is perhaps not surprising that IL-4 production is 
regulated differently under these varying conditions of THC administration; 
furthermore, the studies suggest that Lp immunization under these conditions 
results in primarily a Th1 response and that the suppression of this response by 
THC is mediated by mechanisms independent of IL-4 production. 
 
THC suppression of DC IL-12p40 production mediated loss of Th1 
polarization 
 
 The previous studies suggested that THC treatment of DCs suppressed 
their Th1 polarizing function and we wanted to test this directly using an in vitro 
co-cultivation paradigm.  Because IL-12 is potent in directing Th1 cell 
differentiation (109) and because we found that THC suppressed this cytokine in 
Lp-infected DC cultures, we evaluated the Th1 promoting potential (as measured 
by IFN-γ production) of both Lp-loaded DCs and drug-treated DCs in co-culture 
with Lp-primed CD4 T cells as well as the role of IL-12p40 in the response.  The 
data showed that co-culturing Lp-loaded DCs with Lp-primed T cells led to 
enhanced IL-12p40 and IFN-γ production compared to co-culture with unprimed 
T cells, and that THC treatment of the DCs attenuated the production of 
polarizing cytokines (Figure 19).  Furthermore, the addition of exogenous IL-
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12p40 to the THC-treated cultures restored the robust production of both IL-
12p40 and IFN-γ, suggesting that drug suppression of the p40 protein was 
responsible for inhibiting Th1 polarization in the cultures.  IL-12p70 and IL-23 
have also been shown to polarize toward Th1 (75), but drug effects on these 
cytokines were not involved because they could not be detected in the 
supernatants (data not shown).  In addition, IL-10 has been shown to suppress 
Th1 polarization under various conditions (187), but again it was not detected in 
the supernatants so was probably not involved in the drug effect.  These results 
show that IL-12p40 can be a major Th1 polarizing protein and that its 
suppression by THC is a key factor in the drug-induced inhibition of Th1 cell 
development.  In this regard, several other reports have shown that the p40 
protein has Th1 polarizing potential and affinity for IL-12 receptors (22, 31, 66).  
In conclusion, our results show that a major cellular target of THC-induced 
immune suppression of Th1 immunity is the dendritic cell and that the drug 
attenuates polarizing function by suppressing IL-12p40 production and the 
expression of MHC class II, co-stimulatory molecules and Notch ligand Delta4 
(Figure 20).  Although, THC might compromise the host’s ability to fight infection 
it also might be of use in the treatment of chronic inflammatory diseases such as 
coeliac disease and Crohn's disease (63, 153), rheumatoid arthritis (177, 182) 
and systemic lupus (62).  The data reported here suggest that THC and other 
cannabinoids may belong to this group of anti-inflammatory drugs.  
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SUMMARY  
 
The legalization of marijuana has been debated for years because many 
people consider it a relatively benign substance with possible beneficial 
medicinal properties.  Indeed, it is not as addictive as are other drugs such as 
heroin, cocaine or nicotine (122).  However, in the aspect of health impact, the 
potential risks and benefits of marijuana use remain to be further explored.  The 
current study investigated the role of cannabinoids in the immune system and 
found multiple effects of THC on the cellular immune function of DCs. 
Based on the data presented in this study, it appears that during Lp 
infection, immature DCs are capable of capturing Lp and its associated antigen.  
This leads to maturation and activation of DCs with up-regulation of MHC class II 
and other costimulatory molecules and the production of proinflammatory 
cytokines.  Secretion of IL-12p40 by DCs plays a critical role in activation and 
differentiation of Th1 cells which are required for control and elimination of 
infection; activation of macrophages and B cells and the production of pathogen 
specific neutralizing antibodies such as IgG2a, which also contribute to host 
resistance and clearing of the infection.  THC, however, suppresses IL-12p40 
production in DCs after Lp infection and down-regulates DC MHC class II and 
several costimulatory molecules including CD86, CD40 and Notch ligand, leading 
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to the depressed Th1 development and immunosuppression against Lp 
challenge.   
Current data suggest the involvement of Gi signaling and cannabinoid 
receptors in THC suppression of IL-12p40 and probably also MHC (67) and 
costimulatory molecules.  The mechanism may involve the activation of 
phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and its downstream 
MAP kinases activation.  It was recently reported that inhibition of IL-12 by 
ligands for Gi-protein-coupled receptors was mediated by the activation of 
PI3K/Akt signaling and the MAP kinase JNK (95).  Gi receptors for THC may also 
stimulate Akt and JNK and consequently suppress the activation of NF-kappaB 
and p38 required for DC activation and maturation (190) (Figure 21).  Our results 
also suggest the existence of mechanisms other than Gi signaling.  One possible 
candidate is PPAR, which belongs to the nuclear receptor superfamily and can 
be activated by cannabinoid ligands such as 2-AG (154) and AJA (24).  Recent 
studies showed that activation of PPARγ or PPARα may help to control 
inflammatory responses through inhibiting NF-kappaB transactivation, which is 
critical for DC immunostimulatory functions (141, 156, 190) (Figure 21).   
Due to their immunomodulation effects, cannabinoids have been recently 
used in the treatment of several chronic inflammatory disorders.  For example, 
diabetes is associated with the autoimmune destruction of pancreatic β cells and 
insulin deficiency.  Studies show that THC attenuates the severity of disease in 
an animal model and is associated with the suppression of IFN-γ, TNF-α and IL-
12 mRNA expression in pancreatic tissues from mice (99).  More recently, 
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Steffens et al. reported that oral administration of THC significantly inhibited the 
progression of atherosclerosis in a murine model, suggesting a beneficial effect 
of cannabinoids in this chronic inflammatory disease of the vessels (157, 170).  
Moreover,  in a model of multiple sclerosis, an autoimmune inflammatory disease 
of the CNS, the cannabinoid, Win55,212, showed suppression of disease 
associated with the suppression of T cell proliferation and IFN-γ secretion and 
other pro-inflammatory, Th1-type cytokines,  such as IL-1β and TNF-α (35).  All 
of these studies suggest the potential therapeutic uses of cannabinoids.  Our 
studies reported here address possible cellular mechanisms of cannabinoid-
induced suppression of Th1 immunity. By investigating the effect of cannabinoids 
on DCs controlling antigen-driven T-cell polarization, our results not only serve to 
expand our understanding of cannabinoid effects in the immune system, but also 
provide clues to the cellular mechanism involved and therefore offer more 
specific targets for future drug development in the treatment of chronic 
inflammatory diseases.     
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